Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K
Ludwig Institute for Cancer Research, Clinical Group, Uppsala, Sweden.
Cancer. 1990 May 1;65(9):1883-90. doi: 10.1002/1097-0142(19900501)65:9<1883::aid-cncr2820650902>3.0.co;2-3.
A prospective study was performed on 84 patients with neuroendocrine pancreatic tumors. Fifty-nine (70%) had malignant tumors and received causal medical treatment. Streptozotocin in combination with 5-fluorouracil or doxorubicin was used as first-line treatment and produced overall objective responses in 20 of 44 (45%) patients with a median duration of response of 27.5 months. Thirty-two patients who failed on chemotherapy subsequently received interferon treatment and 20 (63%) responded objectively with a median duration of 20.5 months. Octreotide, third-line treatment in 14 patients, produced objective responses in four patients (28%) (median duration of response, 16 months). The median survival from diagnosis in malignant cases was 6.7 years. Even if none of the current medical therapies are curative for patients with malignant endocrine pancreatic tumors, a prolonged survival would be observed during the last decade. Since the age at diagnosis has not been dramatically reduced despite improvements in diagnostic methods, the prolonged survival might be attributed to causal medical treatment.
对84例胰腺神经内分泌肿瘤患者进行了一项前瞻性研究。其中59例（70%）患有恶性肿瘤并接受了病因治疗。链脲佐菌素联合5-氟尿嘧啶或多柔比星被用作一线治疗，44例患者中有20例（45%）产生了总体客观反应，反应的中位持续时间为27.5个月。32例化疗失败的患者随后接受了干扰素治疗，其中20例（63%）客观缓解，中位缓解持续时间为20.5个月。奥曲肽用于14例患者的三线治疗，4例患者（28%）产生了客观反应（反应的中位持续时间为16个月）。恶性病例从诊断开始的中位生存期为6.7年。即使目前没有一种药物疗法能治愈恶性胰腺内分泌肿瘤患者，但在过去十年中观察到生存期延长。尽管诊断方法有所改进，但诊断时的年龄并未显著降低，生存期延长可能归因于病因治疗。
